ScholarIQanswers from OpenAlex
Verizon (United States)
InstitutionResearch output, impact & collaborations
Verizon (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Verizon (United States)?
ScholarIQrecord summary
Verizon (United States) is a research organisation in New York, US. OpenAlex records 3,558 works and 101,264 citations for it. 927 researchers list it as their most recent affiliation.
How many works does Verizon (United States) have?
ScholarIQindexed works
Verizon (United States) has 3,558 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Verizon (United States) have?
ScholarIQcitation count
Verizon (United States) has 101,264 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Verizon (United States)?
ScholarIQresearcher count
Verizon (United States) has 927 researchers in the ScholarIQ index.
What is the average h-index at Verizon (United States)?
ScholarIQavg h-index
Verizon (United States) has an average h-index of 71.5 in OpenAlex.
What is the ROR of Verizon (United States)?
ScholarIQror
The ROR for Verizon (United States) is on the source record.
What is the OpenAlex record for Verizon (United States)?
ScholarIQopenalex
The OpenAlex for Verizon (United States) is on the source record.
What is the Wikidata of Verizon (United States)?
ScholarIQwikidata
The Wikidata for Verizon (United States) is on the source record.
Who are the most-cited researchers behind Verizon (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Verizon (United States)?
ScholarIQmost cited works
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark
How much of the research on Verizon (United States) is open access?
ScholarIQopen access share
100%OPEN ACCESS